In multiple mouse tumour models, pharmacological inhibition, genetic depletion, or PROTAC‐induced degradation of MAP4K1 were shown to be more effective than genetic depletion of PD‐1 in CAR‐T cells in improving the efficacy of CAR‐T cell‐based therapies.37 This evidence concerns the gene MAP4K1 and neoplasm.